[Toxicological studies on a new cephamycin, MT-141. V. Its subacute toxicity in beagle dogs].
The 30-day subacute toxicity of MT-141 was studied in adult Beagle dogs with intravenous (i.v.) administrations of 100 to 1,200 mg/kg/day. The obtained results were as follows. MT-141 at the doses lower than 800 mg/kg/day i.v. had no toxicity in male and female Beagle dogs. An increase in water intake was closely related to that in urine excretion after i.v. treatments with 1,200 mg/kg/day of MT-141 in the males and females. MT-141 at the doses higher than 1,000 mg/kg/day i.v. of MT-141 caused slight local irritation at the site of injection in the males and females. In the females, the dose-dependent changes induced by treatments with the doses above 1,000 mg/kg/day i.v. of MT-141 were a significant decrease in the level of serum K and a significant increase in the activity of serum LAP. In the males, this compound produced significant dose-dependent changes in toxicological parameters such as a decrease in the activity of GOT at the doses higher than 1,000 mg/kg/day i.v., a descent in the levels of U-K, U-Cl and OP at the dose of 1,200 mg/kg/day i.v., an elevation in the level of serum alpha 1- and alpha 2-G, and an increase in the volume of excreted urine at the dose of 1,200 mg/kg/day i.v. It is concluded from the above-mentioned results that the maximal "no effective" dose of MT-141 is 800 mg/kg/day i.v. and the toxic dose of MT-141 is above 1,000 mg/kg/day i.v. in male and female Beagle dogs.
D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D002513:Cephamycins / Q000633:toxicity*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects; D005260:Female; D007275:Injections, Intravenous; D007659:Ketones / Q000652:urine; D007931:Leucyl Aminopeptidase / Q000097:blood; D008297:Male; D011188:Potassium / Q000097:blood
D002513:Cephamycins; D007659:Ketones; D001219:Aspartate Aminotransferases; D007931:Leucyl Aminopeptidase; C046079:cefminox; D011188:Potassium